Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medx Health Corp V.MDX

Alternate Symbol(s):  MDXHF

MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use technology utilizing light and its remittance to view suspicious moles and lesions up to two millimeters (mm) beneath in a pain-free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.


TSXV:MDX - Post by User

Post by hobbs2969on Sep 22, 2020 11:05am
134 Views
Post# 31597197

A New Device to Evaluate Melanomas Posted on Agoracom Today

A New Device to Evaluate Melanomas Posted on Agoracom TodayIs this our new competition?

NEW YORK, NY, USA, September 15, 2020 /EINPresswire.com/ -- Melanoma is the sixth most common type of cancer. Almost 200,000 Americans, men and women, are diagnosed with melanoma every year with over 7,000 deaths because of melanoma annually. If caught early, melanomas can be more easily managed and cut out and carries a much better clinical course. A new study published in SKIN: The Journal of Cutaneous Medicine® has found that using a new FDA-approved device can not only make the diagnosis of melanoma more accurate, but also reduce the need to perform any surgeries to make the diagnosis. The device measures how easily electricity can travel around skin cells and generates an easily interpretable score between 0 to 10, where higher numbers are more suggestive of melanoma than lower numbers.

Graham H. Litchman, DO, MS and colleagues showed 43 randomly chosen pictures of confirmed melanomas and non-cancerous skin spots to over 500 dermatologists, dermatology residents, and nurse practitioners/physician assistants. They showed these 43 images to clinicians and asked them would they consider surgery to diagnose the melanoma. They then showed them the 43 images again, this time with a score generated by the device, and asked them would they now consider surgery.

The study found that not only did using this new technology reduce the number of missed melanomas from 80 to 153 down to 7 to 13 but did so while also reducing the number of “theoretical” surgeries by over 15%. Furthermore, regardless of experience, the authors found that this technology improved decision making across the board.

The authors concluded that this technology could have the best benefit for suspicious skin spots that are “on the fence” when examined by a doctor and might not have all the hallmarks for melanoma skin cancer. Incorporating this technology may have even greater social and economic impact by reducing potentially unnecessary surgeries and associated anxiety and may even be able to catch melanomas earlier than if a more conservative watch-and-wait approach were used to see if the suspicious skin spot grows, changes color or evolves in a concerning way.

SKIN: The Journal of Cutaneous Medicine® is a peer-reviewed online medical journal that is the official journal of The National Society for Cutaneous Medicine. The mission of SKIN is to provide an enhanced and accelerated route to disseminate new dermatologic knowledge for all aspects of cutaneous disease.

Source: https://www.einnews.com/pr_news/526105443/the-future-of-skin-cancer-detection-diagnosis-without-needing-to-be-cut

<< Previous
Bullboard Posts
Next >>